Phase 4 Myeloma Trial, Recruiting NCT07094048 Sponsor: CHU de Quebec-Universite Laval Condition: Myeloma
Back to Myeloma

Phase 4 Myeloma Trial, Recruiting

NCT07094048
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with multiple myeloma (a type of blood cancer)
  • People who are 18 years old or older
  • People who have already received at least one previous cancer treatment for their multiple myeloma
  • People who are starting a specific type of treatment called a BCMA-directed T-cell Engager therapy
  • People whether or not they have previously received immunoglobulin (antibody) replacement therapy

Who may not be able to join:

  • People who are under 18 years old
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Dr Julie Côté, MD,FRCPC, CHU de Québec-Université Laval

Phone: 1-418-525-4444

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
CHU de Quebec-Universite Laval
Registry
ClinicalTrials.gov
Start date
5 January 2026
Est. completion
1 December 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Severe infections

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov